Page 60 - SaxoCell Annual Report 2021
P. 60
SaxoCell SYSTEMS
The production of ATMPs by means of widely applicable,
standardized processes on an industrial scale requires
automation solutions. Initial concepts for the high-
throughput manufacture of ATMPs have already been
SaxoCell Platforms PD Dr. Stephan Fricke automated ATMP production are to be developed and the
outlined in SaxoCell. Specifically, protocols and concepts for
link to new types of quality control will be addressed. The
aim is to map this standardization strategy in the project as
Fraunhofer IZI
far as possible using generic process modules.
In addition, ATMP manufacturing processes may benefit from
machine learning algorithms, in order to automate the safe
and efficient production of cell therapeutics. This will enable
stakeholders to move towards robust scaling of cell
production for clinical purposes. All aspects will be
developed with Good Manufacturing Practice (GMP)
Dr. Ulrich Blache compatibility in mind and GMP training methods will be
Fraunhofer IZI developed.
55
